NO951608L - Use of BHAP Compounds in Combination with Other Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of HIV Infection - Google Patents

Use of BHAP Compounds in Combination with Other Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of HIV Infection

Info

Publication number
NO951608L
NO951608L NO951608A NO951608A NO951608L NO 951608 L NO951608 L NO 951608L NO 951608 A NO951608 A NO 951608A NO 951608 A NO951608 A NO 951608A NO 951608 L NO951608 L NO 951608L
Authority
NO
Norway
Prior art keywords
hiv
treatment
bhap
compounds
combination
Prior art date
Application number
NO951608A
Other languages
Norwegian (no)
Other versions
NO951608D0 (en
Inventor
William Gary Tarpley
Thomas Jerome Dueweke
Donald Herman M D Batts
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of NO951608D0 publication Critical patent/NO951608D0/en
Publication of NO951608L publication Critical patent/NO951608L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse er metoder for behandling av et HlV-posi- tivt menneske som omfatter (l) admini- strering til det HIV-positive individ av en sensibiliserende effektiv mengde av en sensibiliserende HIV-1-inhibitor inntil forøkt sensibilitet overfor et ikke-nukleosid HlV-behandlingslege- middel utvikles, (2) administrering til det HIV-positive individ av en effektiv mengde av et ikke-nukleosid HlV-behand- lingslegemiddel. En alternativ metode er en metode for behandling av et HIV- positivt menneske som omfatter admini- strering til det HIV-positive individ av en sensibiliserende effektiv mengde av en eller flere sensibiliserende HIV- 1-inhibitorer samtidig med en effektiv mengde av et ikke-nukleosid HlV-behand- lingslegemiddel.The present invention is methods of treating an HIV positive human comprising (l) administering to the HIV positive individual a sensitizing effective amount of a sensitizing HIV-1 inhibitor until increased sensitivity to a non-nucleoside HIV -treatment drug is developed, (2) administration to the HIV-positive individual of an effective amount of a non-nucleoside HIV treatment drug. An alternative method is a method of treating an HIV-positive human comprising administering to the HIV-positive individual a sensitizing effective amount of one or more sensitizing HIV-1 inhibitors simultaneously with an effective amount of a non-nucleoside. HLV treatment drug.

NO951608A 1992-10-28 1995-04-27 Use of BHAP Compounds in Combination with Other Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of HIV Infection NO951608L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96763992A 1992-10-28 1992-10-28
US1711993A 1993-02-12 1993-02-12
PCT/US1993/008354 WO1994009781A1 (en) 1992-10-28 1993-09-10 Use of bhap compounds in combination with other non-nucleoside reverse transcriptase inhibitors for the treatment of hiv infection

Publications (2)

Publication Number Publication Date
NO951608D0 NO951608D0 (en) 1995-04-27
NO951608L true NO951608L (en) 1995-06-28

Family

ID=26689480

Family Applications (1)

Application Number Title Priority Date Filing Date
NO951608A NO951608L (en) 1992-10-28 1995-04-27 Use of BHAP Compounds in Combination with Other Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of HIV Infection

Country Status (12)

Country Link
EP (1) EP0666744A1 (en)
JP (1) JPH08502745A (en)
KR (1) KR950703958A (en)
AU (1) AU4848293A (en)
CA (1) CA2145545A1 (en)
CZ (1) CZ69695A3 (en)
FI (1) FI952018A0 (en)
HU (1) HUT72050A (en)
MX (1) MX9306031A (en)
NO (1) NO951608L (en)
PL (1) PL308551A1 (en)
WO (1) WO1994009781A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW406075B (en) * 1994-12-13 2000-09-21 Upjohn Co Alkyl substituted piperidinyl and piperazinyl anti-AIDS compounds
US6803362B2 (en) 2001-03-09 2004-10-12 Ortho-Mcneil Pharmaceutical Inc. Heterocyclic compounds
UA79309C2 (en) 2002-09-06 2007-06-11 Janssen Pharmaceutica Nv Heterocyclic compounds
US8541407B2 (en) 2010-03-31 2013-09-24 Arqule, Inc. Substituted benzo-pyrido-triazolo-diazepine compounds
US8569331B2 (en) 2010-11-01 2013-10-29 Arqule, Inc. Substituted benzo[f]lmidazo[1,2-d]pyrido[2,3-b][1,4]diazepine compounds

Also Published As

Publication number Publication date
JPH08502745A (en) 1996-03-26
FI952018A (en) 1995-04-27
MX9306031A (en) 1994-04-29
EP0666744A1 (en) 1995-08-16
NO951608D0 (en) 1995-04-27
WO1994009781A1 (en) 1994-05-11
KR950703958A (en) 1995-11-17
FI952018A0 (en) 1995-04-27
CZ69695A3 (en) 1995-12-13
HUT72050A (en) 1996-03-28
PL308551A1 (en) 1995-08-21
CA2145545A1 (en) 1994-05-11
HU9501218D0 (en) 1995-06-28
AU4848293A (en) 1994-05-24

Similar Documents

Publication Publication Date Title
DE69129800D1 (en) TREATMENT OF HUMAN RETROVIRUS INFECTIONS WITH 2 ', 3'-DIDEOXYINOSINE
DE69814049D1 (en) SUBSTITUTED BENZIMIDAZOLES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
BR9608265A (en) Alpha-substituted alkylether and pyrimidine-thioalkyl compounds
ATE93138T1 (en) USE OF INSULIN SENSITIZING AGENTS TO TREAT HYPERTENSION.
DK524788A (en) APPLICATION OF MORPHINE ANTAGONISTS FOR THE PREPARATION OF IMMUNO MODULATING AND ANTIVIRAL EFFECTS, IN PARTICULAR FOR TREATMENT OF ACQUIRED IMMUNDEFECT CONDITIONS
DE69019533D1 (en) TREATMENT OF HIV INFECTIONS AND USEFUL LINKS THEREFOR.
DK261490D0 (en) NEW PHARMACEUTICAL COMPOUND
KR910700045A (en) Treatment of HIV-Related Diseases
DE69414708D1 (en) CONNECTIONS AND METHODS FOR INHIBITING HIV AND RELATED VIRUSES
NO951608L (en) Use of BHAP Compounds in Combination with Other Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of HIV Infection
KR890000097A (en) Glycoprotein Treatment Inhibitors with Antiretrovirus Activity
Kasbekar Studies of resting isolated frog gastric mucosa.
DE69909747D1 (en) PHARMACEUTICAL COMPOSITION, CONTAINING PEG-ASPARAGINASE, FOR THE TREATMENT OF HIV INFECTIONS
EA199700150A1 (en) COMBINED TREATMENT WITH RESPECT OF HIV INFECTION USING HIV PROTASE INHIBITOR INDINAVIAR AND REVERSE TRANSCRIPTASE INHIBITOR 3TC, OPTIONALLY TOGETHER WITH AZT, ddI OR ddC
DK0859613T3 (en) Use of flupirtine for the prevention and treatment of diseases associated with damage to the hemopoietic cell system
KR950702838A (en) Method for inhibiting HIV replication using IL-4 using interleukin-4 (IL-4)
WO1997026880A3 (en) Use of a combination of delavirdine and one or more protease inhibitors in hiv-1 infected patients
EA200000513A1 (en) COMBINED THERAPY FOR THE TREATMENT OF AIDS
SE7701441L (en) NEW PIPERAZINYLURACIL SALT
DK1143976T3 (en) Beta-D-2 ', 3'-didehydro-2', 3'-dideoxy-5-fluorocytidine for use in the treatment of HIV infections
RU94032792A (en) Application of 5htia-antagonists for tobacco use stopping
DK0910405T3 (en) Vaccine containing caprine arthritis encephalitis virus and use for immune protection against HIV-1 infection
UA31078A (en) HUMAN IMMUNODEFICIENCY VIRUS INHIBITOR (DARIMID)
NO931338L (en) RELATIONSHIPS AND PROCEDURES FOR INHIBITING HIV AND RELATED VIRUSES
RU94038588A (en) Method of secondary immunodeficiency treatment